Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews' Q2 Revenues Down; Cuts Net Loss

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GeneNews today reported that its second-quarter revenues declined to C$19,044 (US$18,282) from C$113,244, as it cut its net loss.

The Toronto-based molecular diagnostics firm's revenues dropped sharply due to a C$96,744 milestone payment it received in 2009 that was not repeated for the most recently completed quarter.

GeneNews is in the process of commercializing its ColonSentry blood-based test, which uses biomarkers to determine a person's current risk for colorectal cancer.

"[A]s we move into the second half of the year, we will continue to work with our US marketing partner, Enzo Clinical Labs, and our Chinese marketing partner, GeneDiagnostics, as they prepare to launch ColonSentry in their respective territories," GeneNews President and COO Gailina Liew said in a statement. "At the same time, we will continue to pursue financing activities and discussions with additional potential ColonSentry marketing and strategic partners for other regions of the United States, Europe, and Asia."

GeneNews posted a net loss of C$1.3 million, or C$.02 per share, for the three-month period ended June 30, compared to a net loss of C$1.8 million, or C$.03 per share, for the second quarter of 2009.

Its R&D spending declined to C$518,446 from C$736,197 year over year, while its SG&A expenses fell sharply to C$304,645 from C$492,080. The drop in R&D was the result of reductions in its scientific and technical staff required to support its ColonSentry test service.

GeneNews finished the quarter with C$1.1 million in cash, cash equivalents, cash held in trust, and short-term investments. The firm noted that it has retained Dundee Securities and Reedland Capital Partners to assist it in expanding its shareholder base and accessing additional working capital.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.